»
Medicinal Chemistry of Anticancer Drugs
 
 

Medicinal Chemistry of Anticancer Drugs, 2nd Edition

 
Medicinal Chemistry of Anticancer Drugs, 2nd Edition,ISBN9780444626493
 
 
 

Elsevier Science

9780444626493

9780444626677

768

235 X 191

A concise, intermediate level book which bridges the gap between elementary sources and primary literature

Print Book + eBook

USD 240.00
USD 400.00

Buy both together and save 40%

Print Book

Paperback

In Stock

Estimated Delivery Time
USD 200.00

eBook
eBook Overview

DRM-free included formats : EPUB, Mobi (for Kindle), PDF

VST (VitalSource Bookshelf) format

USD 200.00
Add to Cart
 
 

Key Features

  • Presents information in a clear and concise way using a large number of figures
  • Historical background provides insights on how the process of drug discovery in the anticancer field has evolved
  • Extensive references to primary literature

Description

Medicinal Chemistry of Anticancer Drugs, Second Edition, provides an updated treatment from the point of view of medicinal chemistry and drug design, focusing on the mechanism of action of antitumor drugs from the molecular level, and on the relationship between chemical structure and chemical and biochemical reactivity of antitumor agents.

Antitumor chemotherapy is a very active field of research, and a huge amount of information on the topic is generated every year. Cytotoxic chemotherapy is gradually being supplemented by a new generation of drugs that recognize specific targets on the surface or inside cancer cells, and resistance to antitumor drugs continues to be investigated. While these therapies are in their infancy, they hold promise of more effective therapies with fewer side effects.

Although many books are available that deal with clinical aspects of cancer chemotherapy, this book provides a sorely needed update from the point of view of medicinal chemistry and drug design.

Readership

For researchers in pharmaceutical, medicinal and organic chemistry departments in both academia and industry. Practitioners requiring an understanding of structure-activity relationships in oncology / cancer research. Advanced undergraduate and graduate students in medicinal chemistry and pharmacology.

Medicinal Chemistry of Anticancer Drugs, 2nd Edition

  • Foreword
  • Preface
  • Abbreviations
  • Chapter 1: General Aspects of Cancer Chemotherapy
    • Abstract
    • 1. Introduction: Some General Comments About Cancer
    • 2 Tumorigenesis and Oncogenes: Pharmacogenomics
    • 3 Early Diagnosis of Cancer and Its Therapeutic Relevance
    • 4 A Brief History of Cancer Chemotherapy
    • 5 General Comments About Anticancer Drug Discovery
    • 6 Combination Therapy and Personalized Anticancer Treatments
    • 7 Natural Products in Cancer Chemotherapy
    • 8 A Brief Comment About Cancer Nanotechnology
    • 9 Summary of FDA-Approved Anticancer Drugs
  • Chapter 2: Antimetabolites That Interfere with Nucleic Acid Biosynthesis
    • Abstract
    • 1 Introduction
    • 2 Inhibitors of the Biosynthesis of Uridylic Acid
    • 3 Inhibitors of Ribonucleotide Reductase
    • 4 Inhibitors of the Biosynthesis of Thymidilic Acid
    • 5 Inhibitors of Dihydrofolate Reductase
    • 6 Inhibitors of the De Novo Purine Biosynthesis Pathway
    • 7 Inhibitors of Adenosine Deaminase
    • 8 Inhibitors of Late Stages in DNA Synthesis
    • 9 Antimetabolite Enzymes
  • Chapter 3: Anticancer Drugs That Modulate Hormone Action
    • Abstract
    • 1 Introduction
    • 2 Estrogens and Their Involvement in Carcinogenesis
    • 3 Antiestrogens as Antitumor Drugs
    • 4 Aromatase Inhibitors
    • 5 Steroid Sulfatase Inhibitors
    • 6 Androgen-Related Antitumor Agents
    • 7 Regulation of Gonadotropin-Releasing Hormone: Control of the Hypothalamic–Pituitary–Gonadal axis
    • 8 Miscellaneous Steroid Hormone-Related Anticancer Therapy
    • 9 Compounds Acting on Other Proteins of the Nuclear Receptor Superfamily: Retinoids
    • 10 PPAR Ligands as Antitumor Agents
    • 11 Somatostatin Analogs in Neuroendocrine Tumors
  • Chapter 4: Anticancer Drugs Acting via Radical Species: Radiotherapy and Photodynamic Therapy of Cancer
    • Abstract
    • 1 Introduction: Radicals and Other Reactive Oxygen Species
    • 2 Biological Effects of Reactive Oxygen Species
    • 3 Anthracyclines and Their Analogs
    • 4 Mitoxantrone and Related Quinones
    • 5 Actinomycin D
    • 6 Chartreusin, Elsamicin A, and Related Compounds
    • 7 Bleomycins
    • 8 Enediyne Antibiotics
    • 9 Tirapazamine
    • 10 Penclomedine
    • 11 Radiotherapy and Radiosensitizers
    • 12 Photodynamic Therapy of Cancer
  • Chapter 5: DNA Alkylating Agents
    • Abstract
    • 1 Introduction
    • 2 Nitrogen Mustards
    • 3 Aziridines (Ethyleneimines)
    • 4 Epoxides
    • 5 Methanesulfonates
    • 6 Nitrosoureas
    • 7 Triazenes
    • 8 Methylhydrazines
    • 9 1,3,5-Triazines: Hexamethylmelamine and Trimelamol
    • 10 Transition Metal Species
    • 11 Miscellaneous Alkylating and Acylating Antitumor Agents
  • Chapter 6: Anticancer Drugs That Interact with the DNA Minor Groove
    • Abstract
    • 1 Introduction
    • 2 Netropsin, Distamycin, and Related Compounds
    • 3 Mitomycins
    • 4 Tetrahydroisoquinoline Alkaloids
    • 5 Cyclopropylindole Alkylating Agents
    • 6 Irofulven
    • 7 Pyrrolo[1,4]benzodiazepines
  • Chapter 7: Other Anticancer Drugs Targeting DNA and DNA-Associated Enzymes
    • Abstract
    • 1 DNA Intercalation and Its Consequences
    • 2 Monofunctional Intercalating Agents
    • 3 Bifunctional Intercalating Agents
    • 4 Indirect DNA Damage by DNA Topoisomerase Inhibitors
    • 5 Specific Topoisomerase I Inhibitors
    • 6 Topoisomerase II Poisons
    • 7 Topoisomerase II Catalytic Inhibitors
    • 8 Telomerase Inhibitors and Other Anticancer Approaches Targeting TelomerEs
    • 9 DNA Repair Inhibitors
  • Chapter 8: Epigenetic Therapy of Cancer
    • Abstract
    • 1 Introduction
    • 2 Inhibitors of DNA Methylation: Reactivation of Silenced Genes
    • 3 Inhibitors of Histone and Other Protein Deacetylases
    • 4 Regulators of Histone Methylation
  • Chapter 9: Anticancer Drugs Targeting Tubulin and Microtubules
    • Abstract
    • 1 Introduction
    • 2 Drugs That Inhibit Microtubule Polymerization
    • 3 Microtubule-Stabilizing Agents: Compounds Binding at the Taxane Site
    • 4 Miscellaneous Anticancer Drugs Acting on Novel Sites of Tubuline
    • 5 Antivascular Effects of Microtubule-Targeted Agents
    • 6 Mitotic Kinesin Inhibitors
  • Chapter 10: Drugs That Inhibit Signaling Pathways for Tumor Cell Growth and Proliferation: Kinase Inhibitors
    • Abstract
    • 1 Introduction
    • 2 Oncogenes and Signal Transduction
    • 3 The Role of Protein Kinases in Cancer: Signaling Pathways Related to Kinases
    • 4 Inhibitors of Tyrosine Kinases
    • 5 Inhibitors of Serine–Threonine Kinases
    • 6 Inhibitors of the Ras/Raf/MEK Signaling Pathway
    • 7 Transforming Growth Factor-β–Smad Signaling
    • 8 Glucose Metabolism and Cancer: Inhibitors of Kinases Involved in Anaerobic Glycolysis
  • Chapter 11: Other Nonbiological Approaches to Targeted Cancer Chemotherapy
    • Abstract
    • 1 Introduction
    • 2 Proteolytic Enzymes as Anticancer Targets
    • 3 Heparanase Inhibitors
    • 4 Integrin Antagonists and Inhibitors of Chemokine Receptors
    • 5 Endogenous Inhibitors of Angiogenesis
    • 6 Miscellaneous Antiangiogenic Compounds
    • 7 Drugs Targeting Cancer Stem Cells
    • 8 Inhibitors of Oncogenic Protein–Protein Interactions
    • 9 Anticancer Agents Targeted at the Lysosomes
  • Chapter 12: Biological Therapy of Cancer
    • Abstract
    • 1 Introduction
    • 2 Monoclonal Antibodies against Cancer Cells
    • 3 Cancer Immunotherapy: General Aspects
    • 4 Cancer Vaccines
    • 5 Gene Therapy
    • 6 Antisense Oligonucleotides in Cancer Treatment
    • 7 Bacteria and Bacterial Toxins in Cancer Therapy
  • Chapter 13: Drug Targeting in Anticancer Chemotherapy
    • Abstract
    • 1 Introduction
    • 2 Small-Molecule Prodrugs for Anticancer Drug Targeting
    • 3 Therapeutic Nanoparticles for Drug Delivery in Cancer: General Aspects
    • 4 Polymer Conjugates: Macromolecular Small-Drug Carrier Systems
    • 5 Polymer-Directed Enzyme Prodrug Therapy Approaches
    • 6 Folate Receptor-Targeted Chemotherapy
    • 7 Liposomes and Other Nanoparticles in Anticancer Drug Targeting
  • Chapter 14: Drugs That Modulate Resistance to Antitumor Agents
    • Abstract
    • 1 Introduction
    • 2 ABC Efflux Pumps in Anticancer Drug Resistance
    • 3 Glutathione and Glutathione S-Transferase in Anticancer Drug Resistance
    • 4 Chemosensitizers Targeting DNA Repair Systems
    • 5 Antitumor Drug Resistance Related to Cellular Adhesion Molecules
    • 6 Antitumor Drug Resistance Related to the Extracellular pH: Tumor-Associated Carbonic Anhydrase as an Anticancer Target
    • 7 The Role of the SPARC Protein in Drug Resistance
    • 8 Radioresistance and Tumor Radiosensitization
    • 9 Induced Tumor Chemoresistance
  • Chapter 15: Cancer Chemoprevention
    • Abstract
    • 1 Introduction
    • 2 Cancer Biomarkers, Molecular Medicine, and Individualized Treatments
    • 3 Cancer Chemoprevention
    • 4 Chemopreventive Agents
    • 5 Nutritional Supplements
    • 6 Ligands for Nuclear Receptors in Cancer Chemoprevention
  • Index

Quotes and reviews

"Through a mechanistic approach, this valuable guide provides the reader with the principles of modern drug design methods and their application in the cancer field."--Anticancer Research, Medicinal Chemistry of Anticancer Drugs. Second Edition
 
 
Free Shipping
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy
FAQ

Contact Us